Literature DB >> 30333617

Antibody-mediated protection against Ebola virus.

Erica Ollmann Saphire1,2, Sharon L Schendel3, Bronwyn M Gunn4, Jacob C Milligan3, Galit Alter5.   

Abstract

Recent Ebola virus disease epidemics have highlighted the need for effective vaccines and therapeutics to prevent future outbreaks. Antibodies are clearly critical for control of this deadly disease; however, the specific mechanisms of action of protective antibodies have yet to be defined. In this Perspective we discuss the antibody features that correlate with in vivo protection during infection with Ebola virus, based on the results of a systematic and comprehensive study of antibodies directed against this virus. Although neutralization activity mediated by the Fab domains of the antibody is strongly correlated with protection, recruitment of immune effector functions by the Fc domain has also emerged as a complementary, and sometimes alternative, route to protection. For a subset of antibodies, Fc-mediated clearance and killing of infected cells seems to be the main driver of protection after exposure and mirrors observations in vaccination studies. Continued analysis of antibodies that achieve protection partially or wholly through Fc-mediated functions, the precise functions required, the intersection with specificity and the importance of these functions in different animal models is needed to identify and begin to capitalize on Fc-mediated protection in vaccines and therapeutics alike.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30333617      PMCID: PMC6814399          DOI: 10.1038/s41590-018-0233-9

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  122 in total

Review 1.  Immunology and evolvement of the adenovirus prime, MVA boost Ebola virus vaccine.

Authors:  Yan Zhou; Nancy J Sullivan
Journal:  Curr Opin Immunol       Date:  2015-08-03       Impact factor: 7.486

Review 2.  Production of therapeutic antibodies with controlled fucosylation.

Authors:  Naoko Yamane-Ohnuki; Mitsuo Satoh
Journal:  MAbs       Date:  2009-05-28       Impact factor: 5.857

3.  Ebola virus entry requires the host-programmed recognition of an intracellular receptor.

Authors:  Emily Happy Miller; Gregor Obernosterer; Matthijs Raaben; Andrew S Herbert; Maika S Deffieu; Anuja Krishnan; Esther Ndungo; Rohini G Sandesara; Jan E Carette; Ana I Kuehne; Gordon Ruthel; Suzanne R Pfeffer; John M Dye; Sean P Whelan; Thijn R Brummelkamp; Kartik Chandran
Journal:  EMBO J       Date:  2012-03-06       Impact factor: 11.598

4.  Fc optimization of therapeutic antibodies enhances their ability to kill tumor cells in vitro and controls tumor expansion in vivo via low-affinity activating Fcgamma receptors.

Authors:  Jeffrey B Stavenhagen; Sergey Gorlatov; Nadine Tuaillon; Christopher T Rankin; Hua Li; Stephen Burke; Ling Huang; Sujata Vijh; Syd Johnson; Ezio Bonvini; Scott Koenig
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

5.  Biochemical and structural characterization of cathepsin L-processed Ebola virus glycoprotein: implications for viral entry and immunogenicity.

Authors:  Chantelle L Hood; Jonathan Abraham; Jeffrey C Boyington; Kwanyee Leung; Peter D Kwong; Gary J Nabel
Journal:  J Virol       Date:  2010-01-06       Impact factor: 5.103

6.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

7.  Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity.

Authors:  Stylianos Bournazos; Florian Klein; John Pietzsch; Michael S Seaman; Michel C Nussenzweig; Jeffrey V Ravetch
Journal:  Cell       Date:  2014-09-11       Impact factor: 41.582

Review 8.  Immune correlates of vaccine protection against HIV-1 acquisition.

Authors:  Lawrence Corey; Peter B Gilbert; Georgia D Tomaras; Barton F Haynes; Giuseppe Pantaleo; Anthony S Fauci
Journal:  Sci Transl Med       Date:  2015-10-21       Impact factor: 17.956

9.  Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses.

Authors:  Xiangguo Qiu; Lisa Fernando; Judie B Alimonti; P Leno Melito; Friedericke Feldmann; Daryl Dick; Ute Ströher; Heinz Feldmann; Steven M Jones
Journal:  PLoS One       Date:  2009-05-14       Impact factor: 3.240

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  56 in total

1.  Integration of mechanistic immunological knowledge into a machine learning pipeline improves predictions.

Authors:  Anthony Culos; Amy S Tsai; Natalie Stanley; Martin Becker; Mohammad S Ghaemi; David R McIlwain; Ramin Fallahzadeh; Athena Tanada; Huda Nassar; Camilo Espinosa; Maria Xenochristou; Edward Ganio; Laura Peterson; Xiaoyuan Han; Ina A Stelzer; Kazuo Ando; Dyani Gaudilliere; Thanaphong Phongpreecha; Ivana Marić; Alan L Chang; Gary M Shaw; David K Stevenson; Sean Bendall; Kara L Davis; Wendy Fantl; Garry P Nolan; Trevor Hastie; Robert Tibshirani; Martin S Angst; Brice Gaudilliere; Nima Aghaeepour
Journal:  Nat Mach Intell       Date:  2020-10-12

Review 2.  Expression of mammalian proteins for diagnostics and therapeutics: a review.

Authors:  Jacqueline Kar Kei Mark; Crystale Siew Ying Lim; Fazlina Nordin; Gee Jun Tye
Journal:  Mol Biol Rep       Date:  2022-06-08       Impact factor: 2.742

3.  The C-Terminal Domain of the Sudan Ebolavirus L Protein Is Essential for RNA Binding and Methylation.

Authors:  Coralie Valle; Baptiste Martin; Françoise Debart; Jean-Jacques Vasseur; Isabelle Imbert; Bruno Canard; Bruno Coutard; Etienne Decroly
Journal:  J Virol       Date:  2020-06-01       Impact factor: 5.103

4.  Activity of human serum antibodies in an influenza virus hemagglutinin stalk-based ADCC reporter assay correlates with activity in a CD107a degranulation assay.

Authors:  Veronika Chromikova; Jessica Tan; Sadaf Aslam; Arvind Rajabhathor; Maria Bermudez-Gonzalez; Juan Ayllon; Viviana Simon; Adolfo García-Sastre; Bruno Salaun; Raffael Nachbagauer; Florian Krammer
Journal:  Vaccine       Date:  2020-01-17       Impact factor: 3.641

5.  A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.

Authors:  Bronwyn M Gunn; Richard Lu; Matthew D Slein; Philipp A Ilinykh; Kai Huang; Caroline Atyeo; Sharon L Schendel; Jiyoung Kim; Caitlin Cain; Vicky Roy; Todd J Suscovich; Ayato Takada; Peter J Halfmann; Yoshihiro Kawaoka; Matthias G Pauthner; Mambu Momoh; Augustine Goba; Lansana Kanneh; Kristian G Andersen; John S Schieffelin; Donald Grant; Robert F Garry; Erica Ollmann Saphire; Alexander Bukreyev; Galit Alter
Journal:  Immunity       Date:  2021-04-13       Impact factor: 31.745

Review 6.  SARS-CoV-2 cell entry and targeted antiviral development.

Authors:  Zinuo Chen; Ruikun Du; Jazmin M Galvan Achi; Lijun Rong; Qinghua Cui
Journal:  Acta Pharm Sin B       Date:  2021-05-13       Impact factor: 11.413

Review 7.  Current Status of COVID-19 Vaccine Development: Focusing on Antigen Design and Clinical Trials on Later Stages.

Authors:  Pureum Lee; Chang-Ung Kim; Sang Hawn Seo; Doo-Jin Kim
Journal:  Immune Netw       Date:  2021-02-26       Impact factor: 6.303

8.  Ebola vaccine-induced protection in nonhuman primates correlates with antibody specificity and Fc-mediated effects.

Authors:  Michelle Meyer; Bronwyn M Gunn; Delphine C Malherbe; Karthik Gangavarapu; Asuka Yoshida; Colette Pietzsch; Natalia A Kuzmina; Erica Ollmann Saphire; Peter L Collins; James E Crowe; James J Zhu; Marc A Suchard; Douglas L Brining; Chad E Mire; Robert W Cross; Joan B Geisbert; Siba K Samal; Kristian G Andersen; Galit Alter; Thomas W Geisbert; Alexander Bukreyev
Journal:  Sci Transl Med       Date:  2021-07-14       Impact factor: 17.956

9.  A human antibody of potent efficacy against SARS-CoV-2 in rhesus macaques showed strong blocking activity to B.1.351.

Authors:  Chunyin Gu; Xiaodan Cao; Zongda Wang; Xue Hu; Yanfeng Yao; Yiwu Zhou; Peipei Liu; Xiaowu Liu; Ge Gao; Xiao Hu; Yecheng Zhang; Zhen Chen; Li Gao; Yun Peng; Fangfang Jia; Chao Shan; Li Yu; Kunpeng Liu; Nan Li; Weiwei Guo; Guoping Jiang; Juan Min; Jianjian Zhang; Lu Yang; Meng Shi; Tianquan Hou; Yanan Li; Weichen Liang; Guoqiao Lu; Congyi Yang; Yuting Wang; Kaiwen Xia; Zheng Xiao; Jianhua Xue; Xueyi Huang; Xin Chen; Haixia Ma; Donglin Song; Zhongzong Pan; Xueping Wang; Haibing Guo; Hong Liang; Zhiming Yuan; Wuxiang Guan; Su-Jun Deng
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

10.  Identification of Human SARS-CoV-2 Monoclonal Antibodies from Convalescent Patients Using EBV Immortalization.

Authors:  Rut Valgardsdottir; Irene Cattaneo; Gavino Napolitano; Annibale Raglio; Orietta Spinelli; Silvia Salmoiraghi; Concetta Castilletti; Daniele Lapa; Maria Rosaria Capobianchi; Claudio Farina; Josee Golay
Journal:  Antibodies (Basel)       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.